ETV4 Overexpression

CI-VAR-00003157Explore in graph →CIViC 653

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Lung Neoplasm1
ETV4 Overexpression	Trametinib	Predictive	D	Supports Resistance	3	submitted	EID5121 In vitro studies in KRAS G12C lung cancer cells (CALU1) showed that overexpression of ETV4 modulated resistance to trametinib. PMID 28178529 · Wang et al., 2017 · Open in CIViC	civic
Malignant Pancreatic Neoplasm1
ETV4 Overexpression	Trametinib	Predictive	D	Supports Resistance	3	submitted	EID5119 In vitro studies in KRAS G12V pancreatic cancer cells (PATU8902) showed that overexpression of ETV4 reduced sensitivity to trametinib. PMID 28178529 · Wang et al., 2017 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Prostate Neoplasm1
ETV4 Overexpression	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID1658 Immunohistochemical methods were used to evaluate the expression levels of ETV4 in prostate cancer (PCa) tumor samples. Increased expression of ETV4 was associated with greater Gleason score (P = 0.04… (full text at CIViC) PMID 25544710 · Qi et al., 2015 · Open in CIViC	civic